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ABSTRACT 
 
Type 2 diabetes mellitus (T2DM) is a multifactorial disease, where a combination of 
risk factors interacts and plays different roles, culminating in the disease proper. One 
such risk factor is genetics. Single nucleotide polymorphisms (SNPs) in several genes 
have been implicated in rising T2DM risk; one such gene is the transcription factor 7-
like-2 (TCF7L2), which has been showed to blunt incretin action (specifically glucagon-
like peptide-1, GLP-1), leading to impaired glucose-induced insulin secretion. 
Furthermore, these SNPs were also associated with an impaired therapeutic response to 
the sulfonylurea group of oral antidiabetic agents. To date, there is only one small scale 
study that looked at the effect of SNPs in TCF7L2 on T2DM in a Malaysian population, 
and no studies looking at the effect of these SNPs on therapeutic response to any 
antidiabetic agent in T2DM subjects. Our study attempted to address these deficiencies.  
A total of 1008 subjects comprising of 642 T2DM and 366 non-T2DM subjects, who 
fulfilled the inclusion and exclusion criteria, gave written informed consent to be 
included in this cross-sectional case-control study. Five SNPs in TCF7L2 (rs7903146, 
rs12255372, rs11196205, rs7901605 and rs4506565) were genotyped from peripheral 
leukocytes of the subjects using TaqMan SNP genotyping assays on a real-time PCR 
platform. Anthropometric and treatment data were obtained from interviews and 
medical records. Glycated haemoglobin levels were measured in the T2DM subjects. 
All data were analysed using IBM SPSS Statistics (version 19) and Haploview (version 
4.2) softwares.  
This study showed that in a Malaysian population, the variant alleles of the SNPs 
examined were significantly more common in T2DM compared to non-T2DM subjects. 
The strongest association was observed in rs4506565 (p=5e-4; OR 1.97, CI 1.35 – 
2.88). The haplotype TT containing both variant alleles of rs4506565 and rs7903146 
were significantly more common in the T2DM subjects (p=9.97e-5; OR 1.98, CI 1.41 – 
2.84). A significantly higher mean HbA1c was observed in patients on insulin therapies 
(alone or with oral medications) carrying the TT genotype of rs4506565. In a subset of 
subjects on a combination of metformin and a sulfonylurea drug, there were 
significantly higher mean HbA1c values in heterozygous genotype carriers of 
rs7903146, rs11196205, rs7901695 and rs4506565. In the same subset, heterozygous 
genotype carriers of rs11196205, rs7901695 and rs4506565 were associated 
independently with failure to achieve HbA1c target of 6.5%.  
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In conclusion, TCF7L2 gene polymorphism is associated with T2DM in a Malaysian 
population. Furthermore, carriers of the variant alleles are associated with higher 
HbA1c levels, which could indicate more severe disease.  
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ABSTRAK 
Penyakit diabetes jenis 2 (T2DM) adalah penyakit yang mempunyai faktor risiko yang 
pelbagai, di mana kombinasi faktor-faktor ini berinteraksi dan memainkan peranan 
berbeza, yang akhirnya menghasilkan penyakit tersebut. Salah satu faktor risiko itu 
ialah genetik. Polimorfisme tunggal nukleotida (PTN) dalam beberapa gen telah 
dikaitkan dengan peningkatan risiko T2DM; salah satu gen tersebut adalah transcription 
factor 7-like-2 (TCF7L2) yang menyebabkan pengurangan tindakan hormon-hormon 
incretin (seperti glucagon like peptide-1, GLP-1) lantas menjejaskan rembesan insulin 
yang didorongi glukosa. Selain itu, PTN ini juga dikaitkan dengan pengurangan kesan 
terapi dengan ubat antidiabetik daripada kumpulan sulfonylurea. Pada masa ini, hanya 
terdapat satu kajian kecil yang pernah dijalankan untuk melihat kesan PTN dalam gen 
TCF7L2 ke atas T2DM di kalangan penduduk Malaysia. Tambahan pula, belum lagi 
terdapat kajian yang melihat kesan PTN ini terhadap kesan terapi dengan menggunakan 
mana-mana ubat antidiabetik ataupun insulin dalam pesakit T2DM. 
Sejumlah 1008 subjek yang terdiri daripada 642 pesakit T2DM dan 366 subjek tanpa 
T2DM yang memenuhi kriteria kemasukan dan pengecualian, telah memberi kebenaran 
secara bertulis untuk dimasukkan ke dalam kajian ini. Lima PTN dalam gen TCF7L2 
(rs7903146, rs12255372, rs11196205, rs7901605 dan rs4506565) dianalisa daripada 
DNA sel darah putih subjek-subjek tersebut dengan menggunakan kaedah TaqMan pada 
platform real-time PCR. Maklumat antropometri dan rawatan diperolehi melalui 
temuduga subjek dan rekod perubatan mereka. Tahap glycated haemoglobin juga diukur 
pada subjek T2DM. Semua data dianalisis dengan menggunakan perisian IBM SPSS 
Statistics (versi 19) dan Haploview (versi 4.2). 
Kajian ini menunjukkan bahawa di kalangan sekumpulan penduduk Malaysia, alel 
varian daripada PTN yang diperiksa, lebih biasa dijumpai pada subjek T2DM 
berbanding subjek bukan-T2DM. Perkaitan yang kuat telah diperhatikan bagi 
rs4506565 (p = 5e
-4
, OR 1.97, CI 1.35 - 2.88). Haplotaip TT, yang mengandungi kedua-
dua alel varian rs4506565 dan rs7903146, didapati lebih tinggi frekuensinya dalam 
subjek T2DM (p = 9.97e
-5
; OR 1.98, CI 1.41 - 2.84). Dikalangan pesakit yang 
menerima terapi insulin (tunggal atau beserta ubatan oral), purata HbA1c lebih tinggi 
pada pesakit yang membawa genotip TT rs4506565. Pada subset subjek yang dirawat 
dengan gabungan metformin dan ejen sulfonylurea, purata HbA1c adalah lebih tinggi 
pada pembawa genotip heterozigot rs7903146, rs11196205, rs7901695 dan rs4506565. 
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Pada subset yang sama, pembawa genotip heterozigot rs11196205, rs7901695 dan 
rs4506565 juga dikaitkan dengan kegagalan untuk mencapai sasaran HbA1c sebanyak 
6.5%. 
Kesimpulannya, polimorfisme tunggal nukleotida pada gen TCF7L2 dikaitkan dengan 
T2DM di kalangan penduduk Malaysia. Selain itu, pembawa alel varian dikaitkan 
dengan paras HbA1c yang lebih tinggi, yang mungkin menunjukkan tahap penyakit yang 
lebih teruk. 
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